Middle East & Africa Human Papillomavirus (HPV) Vaccine Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)

No. of Pages: 150
Report Code: BMIRE00026302
Category: Life Sciences
Middle East & Africa Human Papillomavirus (HPV) Vaccine Market
Free Sample Buy Now

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Regional Analysis

6.2 Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Revenue 2020-2028 (US$ Million)
6.3 Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast Analysis

7. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Analysis – by Type

7.1 9-valent HPV Vaccine
  • 7.1.1 Overview
  • 7.1.2 9-valent HPV Vaccine: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.2 Quadrivalent HPV Vaccine
  • 7.2.1 Overview
  • 7.2.2 Quadrivalent HPV Vaccine: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)
7.3 Bivalent HPV Vaccine
  • 7.3.1 Overview
  • 7.3.2 Bivalent HPV Vaccine: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

8. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Analysis – by Dosage

8.1 2 Dose and 3 Dose
  • 8.1.1 Overview
  • 8.1.2 2 Dose and 3 Dose: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

9. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Analysis – by Age

9.1 9 to 14 Years and 15 to 45 Years
  • 9.1.1 Overview
  • 9.1.2 9 to 14 Years and 15 to 45 Years: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

10. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Analysis – by Application

10.1 HPV-Attributable Cancer and Genital Warts
  • 10.1.1 Overview
  • 10.1.2 HPV-Attributable Cancer and Genital Warts: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast, 2020-2028 (US$ Million)

11. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Middle East and Africa Analysis

11.1 Overview

11.2 Middle East and Africa
  • 11.2.1 Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 11.2.1.1 Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 South Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.1.1 South Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.1.2 South Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.1.3 South Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.1.4 South Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.2 Saudi Arabia: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.2.1 Saudi Arabia: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.2.2 Saudi Arabia: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.2.3 Saudi Arabia: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.2.4 Saudi Arabia: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.3 UAE: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.3.1 UAE: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.3.2 UAE: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.3.3 UAE: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.3.4 UAE: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application
  • 11.2.1.4 Rest of Middle East and Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.4.1 Rest of Middle East and Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Type
    • 11.2.1.4.2 Rest of Middle East and Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Dosage
    • 11.2.1.4.3 Rest of Middle East and Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Age
    • 11.2.1.4.4 Rest of Middle East and Africa: Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Breakdown, by Application

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 GlaxoSmithKline plc.
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 Inovio Pharmaceuticals
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 Merck & Co., Inc.
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 R-Pharm
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 Sanofi
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 Serum Institute of India Pvt. Ltd
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
14.7 Walvax Biotechnology Co., Ltd.
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

The List of Companies - Middle East & Africa Human Papillomavirus (HPV) Vaccine Market

  • GlaxoSmithKline plc.
  • Inovio Pharmaceuticals
  • Merck & Co., Inc.
  • R-Pharm
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Walvax Biotechnology Co., Ltd.

    • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)